Author(s): Tofoli GR, Cereda CM, Groppo FC, Volpato MC, FranzMontan M,
Abstract Share this page
Abstract This blinded crossover study evaluated the efficacy and pain sensitivity evoked by a previously reported liposome-encapsulated mepivacaine formulation (Araujo et al., 2004). Thirty healthy volunteers received an intraoral injection (1.8 mL), at four different sessions, of the following formulations: 2\% mepivacaine with 1:100,000 epinephrine (MVC(2\%EPI)), 3\% mepivacaine (MVC(3\%)), and 2 and 3\% liposome-encapsulated mepivacaine (MVC(2\%LUV) and MVC(3\%LUV)). Latency period and duration of anesthesia were assessed by an electrical pulp tester and injection discomfort by a visual analog scale (VAS). Data were analyzed with Tukey-Kramer and Friedman tests (P < 0.05). No significant difference was found regarding latency period (in minutes) among the formulations (P > 0.05). The duration of anesthesia after the injection of MVC(3\%LUV) was higher than the one obtained after the infiltration of MVC(2\%LUV) and of MVC(3\%) (P < 0.05). However, the duration of anesthesia obtained with MVC(3\%) did not differ from the one obtained with MVC(2\%LUV) (P > 0.05). MVC(3\%LUV) showed lower VAS median values than MVC(2\%EPI) (P < 0.05), and there were no significant differences among the others formulations. Liposome-encapsulated 3\% mepivacaine showed longer duration of anesthesia, in comparison to the commercial formulation of MVC(3\%). MVC(2\%LUV) was able to produce a similar duration of anesthesia as the 3\% commercial formulation, despite the 50\% decrease in the anesthetic concentration. Thus, the encapsulation of mepivacaine increased the duration of anesthesia and reduced the injection discomfort caused by vasoconstrictor-associated formulations in healthy volunteers. TRIAL REGISTRATION: ClinicalTrials.gov NCT01032798.
This article was published in J Liposome Res
and referenced in Journal of Antivirals & Antiretrovirals